Autolus Therapeutics plc (AUTL)
AUTL Stock Price Chart
Explore Autolus Therapeutics plc interactive price chart. Choose custom timeframes to analyze AUTL price movements and trends.
AUTL Company Profile
Discover essential business fundamentals and corporate details for Autolus Therapeutics plc (AUTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Jun 2018
Employees
647.00
Website
https://www.autolus.comCEO
Christian Martin Itin
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Financial Timeline
Browse a chronological timeline of Autolus Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.23.
Earnings released on 12 Aug 2025
EPS came in at -$0.18 surpassing the estimated -$0.24 by +25.00%, while revenue for the quarter reached $20.92M , missing expectations by -0.74%.
Earnings released on 8 May 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $8.98M , beating expectations by +309.13%.
Earnings released on 20 Mar 2025
EPS came in at -$0.09 surpassing the estimated -$0.21 by +57.14%, while revenue for the quarter reached $29.00K , missing expectations by -98.09%.
Earnings released on 12 Nov 2024
EPS came in at -$0.31 falling short of the estimated -$0.21 by -47.62%.
Earnings released on 8 Aug 2024
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%.
Earnings released on 17 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.10 by -140.00%, while revenue for the quarter reached $10.09M , beating expectations by +0.91%.
Earnings released on 14 Mar 2024
EPS came in at -$0.44 falling short of the estimated -$0.26 by -69.23%, while revenue for the quarter reached $1.78M , beating expectations by +393.06%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $406.00K , beating expectations by +35.33%.
Earnings released on 3 Aug 2023
EPS came in at -$0.26 falling short of the estimated -$0.22 by -18.18%.
Earnings released on 4 May 2023
EPS came in at -$0.23 surpassing the estimated -$0.28 by +17.86%, while revenue for the quarter reached $1.29M , beating expectations by +822.86%.
Earnings released on 7 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.31 by +25.81%, while revenue for the quarter reached $3.83M , beating expectations by +992.86%.
Earnings released on 3 Nov 2022
EPS came in at -$0.47 falling short of the estimated -$0.46 by -2.17%, while revenue for the quarter reached $2.37M , beating expectations by +1.54K%.
Earnings released on 4 Aug 2022
EPS came in at -$0.46 falling short of the estimated -$0.42 by -9.52%.
Earnings released on 5 May 2022
EPS came in at -$0.41 surpassing the estimated -$0.51 by +19.61%, while revenue for the quarter reached $166.00K , missing expectations by -3.17%.
Earnings released on 10 Mar 2022
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $823.00K , missing expectations by -3.72%.
Earnings released on 3 Nov 2021
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $236.00K , missing expectations by -5.60%.
Earnings released on 5 Aug 2021
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%, while revenue for the quarter reached $1.51M , missing expectations by -8.39%.
Earnings released on 6 May 2021
EPS came in at -$0.53 surpassing the estimated -$0.62 by +14.52%, while revenue for the quarter reached $269.00K , missing expectations by -10.45%.
Earnings released on 4 Mar 2021
EPS came in at -$0.82 falling short of the estimated -$0.75 by -9.33%, while revenue for the quarter reached -$873.00K .
Earnings released on 5 Nov 2020
EPS came in at -$0.72 falling short of the estimated -$0.66 by -9.09%, while revenue for the quarter reached $242.00K , missing expectations by -63.90%.
AUTL Stock Performance
Access detailed AUTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.